2008 Washington State Biomedical Device Summit

WBBA is collaborating with several organizations to host the 2008 Washington State Biomedical Device Summit. Focused solely on the region’s medical device sector, the May 15 Summit will attract 200 executives from the medical device industry, researchers, economic development professionals and media. The event will feature a report on key findings of a sector study, a panel discussion with executives from the region’s industry, the launch of the Biomedical Device Innovation Partnership Zone, a showcase medical device products developed or being developed in Washington state and a reception. WBBA’s partners on this effort are enterpriseSeattle, the Economic Development Council of Snohomish County, City of Bothell, University of Washington Bothell, the Prosperity Partnership and the Washington Technology Industry Association. The event is Thursday, May 15 from 4-7 pm, at UW Bothell. WBBA members receive discounted member rate.

Register Now! WBBA Golf Invitational August 22

Local News...

Free News Release Posting & Archiving Service


• Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye  Bayer HealthCare and development partner Regeneron Pharmaceuticals announced that the first patient has been dosed in the new VIEW 2 trial, a second Phase 3 clinical study in a development program evaluating VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration.
  Bayer  May 08, 2008  
  
  
• Zevalin revenues lead Cell Therapeutics's first quarter 2008 financial results  Cell Therapeutics reported financial results for the quarter ended March 31, 2008. Total revenues for the quarter were $3.4 million compared to $20,000 for the first quarter of 2007. Gross product sales of Zevalin(R) (Ibritumomab Tiuxetan) reached $3.8 million in the first quarter of 2008.
  Cell Therapeutics, Inc.  May 08, 2008  
  
  
• AstraZeneca submits sNDA for Seroquel XR for the treatment of generalised anxiety disorder  AstraZeneca announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for SEROQUEL XR(TM) Extended-Release Tablets to seek approval for the treatment of generalised anxiety disorder, including maintenance of antianxiety effect.
  AstraZeneca  May 08, 2008  
  
  
• Dendreon reports first quarter 2008 financial results  Dendreon reported results for the first quarter ended March 31, 2008. Revenue for the first quarter of 2008 was $31,000 compared to $80,000 for the quarter ended March 31, 2007.
  Dendreon Corporation  May 08, 2008  
  
  
• Invitrogen and WARF sign license agreement for human embryonic stem cells  Invitrogen and the Wisconsin Alumni Research Foundation, the private, non-profit patenting and licensing organization for the University of Wisconsin-Madison, announced that they have signed a license for human embryonic stem cell patents for the development of research tools.
  Invitrogen Corporation  May 08, 2008  
  
  

More... | Submit News Release | National News

New Job Postings...

The Recruiter’s Studio: People, Careers, Conversations

• Quality Assurance Associate II, GMP Compliance Targeted Genetics Corporation (WA)
• Preclinical Researcher Calypso® Medical Technologies, Inc. (WA)
• Administrative Assistant I Fred Hutchinson Cancer Research Center (WA)
• Paralegal Bill & Melinda Gates Foundation (WA)
• Manager, Clinical Data Management Poniard Pharmaceuticals, Inc. (WA)

More... | Job Advertising...

Upcoming Events...

Good Clinical Practices Course - San Francisco, CA - May 14-16

Major Live/Webcast LAB Auction - May 15 - 11am (ET)

Join 600 Healthcare Leaders at HDMA DMC & Tech Expo! June 8-11 - Orlando, FL

UW Master in Medical Engineering evening classes: Apply by Aug. 18

• 05/09/2008: Leaders and Innovators of Tomorrow
• 05/10/2008: 17th annual Dreambuilders' Ball
• 05/12/2008: World Pharmaceutical Congress
• 05/12/2008: Advertising, Promotion and Labeling Conference
• 05/12/2008: Generic, Supergenerics & Patent Strategies

More... | Submit Event | Event Advertising...